Onconetix Inc. is a commercial stage biotechnology company specializing in the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for oncology. The company primarily serves clinicians and patients within the oncology market. Onconetix operates on a business model that focuses on developing and bringing to market innovative solutions for cancer treatment and diagnostics. The company generates revenue through the sale of its FDA-approved, once-daily oral therapeutic for benign prostatic hyperplasia (BPH) and other oncology-related products and services. By continually expanding its portfolio in therapeutics, diagnostics, and clinician services, Onconetix aims to meet the evolving healthcare needs of patients and medical professionals.

Keywords: biotechnology, oncology, therapeutics, diagnostics, clinician services, FDA-approved, BPH, cancer treatment, commercialization, healthcare.